ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.5347A>C (p.Met1783Leu) (rs80357012)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000048953 SCV000076966 uncertain significance Hereditary breast and ovarian cancer syndrome 2016-06-21 criteria provided, single submitter clinical testing This sequence change replaces methionine with leucine at codon 1783 of the BRCA1 protein (p.Met1783Leu). The methionine residue is moderately conserved and there is a small physicochemical difference between methionine and leucine. This variant is present in population databases (rs80357012, ExAC 0.03%) but has not been reported in the literature in individuals with a BRCA1-related disease. ClinVar contains an entry for this variant (Variation ID: 55545). An experimental study has shown that this missense change has no effect on BRCA1 protein stability or function (PMID: 20516115). In summary, this variant is a rare missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000220027 SCV000273843 uncertain significance Hereditary cancer-predisposing syndrome 2015-02-12 criteria provided, single submitter clinical testing
Counsyl RCV000112627 SCV000488447 uncertain significance Breast-ovarian cancer, familial 1 2016-03-31 criteria provided, single submitter clinical testing
GeneDx RCV000590089 SCV000570047 uncertain significance not provided 2016-12-16 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.5347A>C at the cDNA level, p.Met1783Leu (M1783L) at the protein level, and results in the change of a Methionine to a Leucine (ATG>CTG). Using alternate nomenclature, this variant would be defined as BRCA1 5466A>C. This variant was observed in at least one individual with diffuse large B-cell lymphoma (Björkman 2015), and functional studies have suggested no impact on BRCA1 function with respect to stability, transcription, and homology-directed repair when compared to wild type (Lee 2010, Lu 2015). BRCA1 Met1783Leu was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Methionine and Leucine share similar properties, this is considered a conservative amino acid substitution. BRCA1 Met1783Leu occurs at a position where amino acids with properties similar to Methionine are tolerated across species and is located within the BRCT 2 domain and a region known to interact with multiple proteins (Paul 2014, UniProt). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA1 Met1783Leu is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Cancer Genetics and Genomics Laboratory,British Columbia Cancer Agency RCV000048953 SCV000586910 uncertain significance Hereditary breast and ovarian cancer syndrome 2017-04-18 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000479927 SCV000591618 uncertain significance not specified 2013-04-30 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000590089 SCV000699246 uncertain significance not provided 2016-11-28 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.5347A>C (p.Met1783Leu) variant involves the alteration of a conserved nucleotide. It is located in BRCT domain of the protein (InterPro). 2/4 in silico tools predict a benign outcome for this substitution. This variant was found in 3/121156 control chromosomes at a frequency of 0.0000248, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). The variant was only found in East Asian cohort with an allele frequency of 3/8650, thus it may be a rare polymorphism in East Asians. It was reported in at least one individual from an HBOC family (Judkins_2005) and in a lymphoma patient (Bjorkman_2015), however without strong evidence for causality such as co-segregation. Functional studies have demonstrated that the variant not to have any impact on HDR, transcription activation, phosphopeptide binding activity and protein stability of BRCA1 protein suggesting for neutrality (Lee_2008, Lu_2015). Multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance without evidence to independently evaluate. Taken together, this variant is currently classified as VUS-possibly benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000590089 SCV000887725 uncertain significance not provided 2017-09-21 criteria provided, single submitter clinical testing
Color RCV000220027 SCV000903153 likely benign Hereditary cancer-predisposing syndrome 2016-07-18 criteria provided, single submitter clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000112627 SCV000145473 uncertain significance Breast-ovarian cancer, familial 1 2004-02-20 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.